Compare Ginkgo Bioworks Holdings Inc (DNA) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Tripadvisor Inc Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while Tripadvisor Inc Common Stock trades at $8.94 (market cap $1.01B). The key difference: Tripadvisor Inc Common Stock is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| DNA | TRIP | |
|---|---|---|
Market Cap | $763.64M | $1.01B |
Volume | 3,204,177 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $16.72 |
52-Week Low | $5.48 | $8.04 |
Typical Hold Time | 7 Days | 57 Days |
Enterprise Value | $865.59M | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
TripAdvisor (TRIP) trades at $8.63, down 42% over the past year and near its 52-week low of $8.27. The stock shows bearish technical signals with recent earnings misses and declining revenue projections for 2026. Despite a low P/S ratio of 0.57, the company faces challenges from AI-driven competition eroding its core travel platform relevance.
The investment outlook remains cautious with analysts divided (21% Buy, 63% Hold) and a $13.58 price target suggesting 57% upside. Key risks include persistent search pressure, TheFork subsidiary sale execution, and competitive threats from AI travel tools. Positive cash flow from operations provides some stability amid the challenging transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
